Opinion|Videos|March 24, 2025
Lifestyle Modifications That Have Been Helpful in RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how lifestyle modifications have become crucial coping strategies for managing multiple myeloma symptoms and treatment side effects, with patients reporting benefits from structured exercise regimens tailored to their energy levels, anti-inflammatory dietary approaches, mindfulness practices and meditation for pain management, consistent sleep hygiene routines, strategic activity pacing throughout the day, hydration protocols, complementary therapies like acupuncture or massage and intentional social engagement—approaches that, while not replacing medical interventions, significantly enhance quality of life and resilience throughout the treatment journey.
Advertisement
Video content above is prompted by the following:
- What lifestyle modifications have you found helpful in managing in your symptoms or side effects?
Advertisement
Related to this article
HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here's what people with cancer should check before picking a plan.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Advertisement
Advertisement